A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer 

Slides:



Advertisements
Similar presentations
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Advertisements

Grace Younes, M.D., Togas Tulandi, M.D., M.H.C.M. 
Demián Glujovsky, M.D., M.Sc., Cynthia Farquhar, M.D., M.P.H. 
Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome.
Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment  Javier Domingo, M.D., Vicente.
The great debate: varicocele treatment and impact on fertility
Patient and cycle characteristics predicting high pregnancy rates with single-embryo transfer: an analysis of the Society for Assisted Reproductive Technology.
Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,
No difference in cycle pregnancy rate and in cumulative live-birth rate between women with surgically treated minimal to mild endometriosis and women.
José Bellver, M. D. , Marco A. B. Melo, M. D. , Ernesto Bosch, M. D
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials  Ana Cobo, Ph.D., César Diaz, M.D. 
Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment.
Zhi-Yong Yang, M.D., Ri-Cheng Chian, Ph.D.  Fertility and Sterility 
The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.
Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study  Nicole Hope, M.B., B.S., Hon., Luk.
Comparison of fallopian tube sperm perfusion and intrauterine tuboperitoneal insemination: a prospective randomized study  Leonidas Mamas, M.D., Ph.D. 
Effect of the initiation of progesterone supplementation in in vitro fertilization–embryo transfer outcomes: a prospective randomized controlled trial 
Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone–stratified, dose–response trial in women undergoing.
Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and.
Medical treatment of ectopic pregnancy: a committee opinion
Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.
A differential cytokine expression profile is induced by highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone in.
The relative contribution of assisted reproductive technologies and ovulation induction to multiple births in the United States 5 years after the Society.
Live birth of twins derived from zona-free oocytes
Increase of success rate for women undergoing embryo transfer by transcutaneous electrical acupoint stimulation: a prospective randomized placebo-controlled.
Evaluation of an ultra-low-dose oral contraceptive for dysmenorrhea: a placebo- controlled, double-blind, randomized trial  Tasuku Harada, M.D., Mikio.
Mikkel Rosendahl, M. D. , Claus Yding Andersen, D. M. Sc
Selection of patients for natural cycle in vitro fertilization combined with in vitro maturation of immature oocytes  Jin-Ho Lim, M.D., Seong-Ho Yang,
A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data 
Oocyte cryopreservation
Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomized study  Ahmet Erdem, M.D., Mehmet Erdem,
Cumulative live-birth rates per total number of embryos needed to reach newborn in consecutive in vitro fertilization (IVF) cycles: a new approach to.
Influence of acupuncture stimulation on pregnancy rates for women undergoing embryo transfer  Caroline Smith, Ph.D., Meaghan Coyle, B.Hlth.Sc. (Acup.),
Follicular and endocrine profiles associated with different GnRH-antagonist regimens: a randomized controlled trial  Juan Antonio García-Velasco, Sanja.
Recombinant FSH versus highly purified FSH in intrauterine insemination: systematic review and metaanalysis  Roberto Matorras, M.D., Ph.D., Carmen Osuna,
Reduced oxygen tension improves embryo quality but not clinical pregnancy rates: a randomized clinical study into ovum donation cycles  Maria J. de los.
A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin.
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis  Dimitra Kyrou,
Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility  Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,
Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized.
Cumulative newborn rates increase with the total number of transferred embryos according to an analysis of 15,792 ovum donation cycles  Nicolás Garrido,
A randomized clinical trial to evaluate the effect of granulocyte-macrophage colony- stimulating factor (GM-CSF) in embryo culture medium for in vitro.
Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study  Carlo.
Tania Luisa Stevenson, M.B.Ch.B., Hany Lashen, F.R.C.O.G. 
Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis 
Jennifer F. Kawwass, M. D. , Sara Crawford, Ph. D. , Donna R
Aaron K. Styer, M. D. , Diane L. Wright, Ph. D. , H. C. L. D. , Anne M
Live babies born per oocyte retrieved in a subpopulation of oocyte donors with repetitive reproductive success  J. Ryan Martin, M.D., Jason G. Bromer,
José Bellver, M. D. , Yanira Ayllón, M. D. , Marcos Ferrando, M. D
Effectiveness of highly purified human menopausal gonadotropin vs
Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin  Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.
Amy Criniti, M. D. , Angela Thyer, M. D. , Gregory Chow, M. D
Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study  Laurel Stadtmauer, M.D.,
Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis  Ernesto Bosch, M.D., Elena.
Blastocyst biopsy with comprehensive chromosome screening and fresh embryo transfer significantly increases in vitro fertilization implantation and delivery.
David H. Barad, M.D., M.S., Norbert Gleicher, M.D. 
Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists 
Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function  David H. Barad, M.D., M.S., Andrea Weghofer,
Randomized controlled trial: effects of acupuncture on pregnancy rates in women undergoing in vitro fertilization  Irene Moy, M.D., Magdy P. Milad, M.D.,
Infertility induced by cancer treatment: inappropriate or no information provided to majority of French survivors of cancer  Julien Mancini, M.D., M.P.H.,
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.
Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.
Oocyte retrieval timing based on spontaneous luteinizing hormone surge during natural cycle in vitro fertilization treatment  Daniel Bodri, M.D., M.Sc.,
Not all twins are monozygotic after elective single embryo transfer: analysis of 32,600 elective single embryo transfer cycles as reported to the Society.
Presentation transcript:

A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer  Paul Devroey, M.D., Ph.D., Antonio Pellicer, M.D., Anders Nyboe Andersen, M.D., Joan-Carles Arce, M.D., Ph.D.  Fertility and Sterility  Volume 97, Issue 3, Pages 561-571 (March 2012) DOI: 10.1016/j.fertnstert.2011.12.016 Copyright © 2012 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Trial flow chart and disposition of patients by trial visit. ITT = intention-to-treat; PP = per-protocol. Fertility and Sterility 2012 97, 561-571DOI: (10.1016/j.fertnstert.2011.12.016) Copyright © 2012 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Pregnancy and live birth data for the fresh cycle per started cycle for (A) the per-protocol (PP) population and (B) the intention-to-treat (ITT) population. Pregnancy and live birth data for the fresh cycle per cycle with transfer for (C) the PP population and (D) the ITT population. Fertility and Sterility 2012 97, 561-571DOI: (10.1016/j.fertnstert.2011.12.016) Copyright © 2012 American Society for Reproductive Medicine Terms and Conditions

Figure 3 Ongoing pregnancy rate in the fresh cycle by oocytes retrieved according to treatment group and end-of-stimulation P levels ≤4 nmol/L and >4 nmol/L (intention-to-treat population). Fertility and Sterility 2012 97, 561-571DOI: (10.1016/j.fertnstert.2011.12.016) Copyright © 2012 American Society for Reproductive Medicine Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.